New York, Dec. 8 - BioAlliance Pharma priced a €30 million initial public offering of common stock.
The Paris-based biopharmaceutical company sold 2,255,640 shares to the public at €13.30 each.
The sale also has a greenshoe for 338,346 shares.
Bryan Garnier & Co. Ltd. and ING Securities Bank (France) were bookrunners for the IPO, which was offered to the public in France and institutions elsewhere, although not in the United States.
BioAlliance Pharma is listed on the Euronext Paris Eurolist.
BioAlliance Pharma specializes in the development of therapeutics to overcome drug resistance, notably through improved patient compliance and targeted delivery of active ingredients.
| Issuer: | BioAlliance Pharma
|
| Issue: | Initial public offering of common stock
|
| Amount: | €30 million
|
| Shares: | 2,255,640
|
| Greenshoe: | 338,346
|
| Price: | €13.30
|
| Pricing date: | Dec. 6, after close
|
| Settlement date: | Dec. 12
|
| Bookrunners: | Bryan Garnier & Co. Ltd., ING Securities Bank (France)
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
